Mubadala launches Mubadala Bio to strengthen UAE life sciences sector

UAE—Mubadala Investment Company PJSC, a sovereign investor based in Abu Dhabi, has launched Mubadala Bio, a new life sciences company dedicated to strengthening the UAE’s life sciences sector and improving health outcomes both locally and globally.

This initiative marks a strategic milestone in Mubadala’s commitment to enhancing healthcare resilience, ensuring drug security, expanding access to high-quality therapeutics and medical devices, and supporting the UAE’s economic diversification towards a knowledge-based economy.

Mubadala Bio’s integrated portfolio includes 10 manufacturing facilities spread across Asia, Africa, and Europe, with six located within the UAE.

These facilities collectively serve over 100 countries worldwide.

The group’s manufacturing capacity is substantial, producing more than 2.5 billion tablets and capsules, 120 million intravenous and injectable products annually, and operating across 110,000 square meters of production space.

This scale enables the production and global distribution of over 10,000 pharmaceutical products.

The company focuses on key therapeutic areas that address some of the world’s most urgent health challenges.

Its portfolio supports the entire continuum of care-from prevention and diagnosis to treatment, ongoing support, and complementary medicine.

Mubadala Bio also emphasizes innovation and local manufacturing by forming long-term strategic partnerships with global industry leaders and leading academic institutions.

This approach helps accelerate biopharmaceutical innovation, nurture world-class talent, and drive rapid advancements in healthcare.

Dr. Bakheet Al Katheeri, CEO of Mubadala’s UAE Investments Platform, highlighted that launching Mubadala Bio is a transformative step toward strengthening national drug security and fostering innovation in life sciences.

He emphasized that this positions Mubadala at the forefront of the industry, enabling long-term economic growth, building a resilient life sciences ecosystem, and elevating Abu Dhabi’s global role in delivering impactful health solutions.

Furthermore, Mubadala’s National Champions continue to accelerate the UAE’s economic diversification by investing in priority sectors and supporting the development of a knowledge-based economy.

Ismail Ali Abdulla, Executive Director of UAE Clusters at Mubadala, added that Mubadala Bio supports the UAE’s ambition to become a global leader in life sciences.

By focusing on local manufacturing and enhancing distribution and logistics capabilities, Mubadala Bio aims to build a resilient and self-sustaining sector that meets current needs and prepares for future challenges.

Aligned with the UAE’s Centennial 2071 vision, Mubadala Bio also focuses on integrated biopharma and pharmaceutical logistics.

It will make its first physical appearance at the upcoming Make it in the Emirates 2025 event, showcasing the UAE’s success in building a competitive life sciences industry and reinforcing its position as a hub for innovation and local manufacturing.

This launch complements Mubadala’s broader efforts, including partnerships like the one with US-based Resilience to establish the region’s first Good Manufacturing Practice (GMP) biopharma facility in Abu Dhabi.

This facility will produce advanced biologics and therapeutics for complex diseases such as cancer, infectious diseases, and autoimmune disorders, further securing the UAE’s pharmaceutical supply chain and boosting the life sciences ecosystem.

Sign up HERE to receive our email newsletters with the latest news and insights from Africa and beyond. Also, follow us on our WhatsApp channel for updates.